# Evaluation of TQ-B3234 Capsules in Patients With Symptomatic, Non-Surgical Type 1 Neurofibromatosis-Associated Plexiform Neurofibromas

> **NCT07407803** · PHASE3 · RECRUITING · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 177 (estimated)

## Conditions studied

- Plexiform Neurofibroma

## Interventions

- **DRUG:** TQ-B3234 capsules
- **DRUG:** TQ-B3234 placebo

## Key facts

- **NCT ID:** NCT07407803
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-31
- **Primary completion:** 2027-12
- **Final completion:** 2028-12
- **Target enrollment:** 177 (ESTIMATED)
- **Last updated:** 2026-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07407803

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07407803, "Evaluation of TQ-B3234 Capsules in Patients With Symptomatic, Non-Surgical Type 1 Neurofibromatosis-Associated Plexiform Neurofibromas". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07407803. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*